联合胱抑素C与肌酐可提高ADPKD中eGFR斜率准确性
在260例常染色体显性多囊肾病(ADPKD)患者中,比较常规eGFRcr、批测eGFRcr、eGFRcys及eGFRcr-cys与碘他拉酸盐测定的mGFR。结果显示eGFRcr-cys斜率与mGFR下降相关性更强(CCC 0.68 vs 0.58,P=0.02),斜率变异性降低可使临床试验样本量减少37%至38%。
要点
- eGFRcr-cys斜率与mGFR下降相关性优于eGFRcr(CCC 0.68 vs 0.58,P=0.02)。
- eGFRcr-cys斜率标准差低于eGFRcr和eGFRcys,变异性更小。
- 斜率变异性降低可使ADPKD临床试验样本量减少37%至38%。
核心结论
- 使用eGFRcr-cys可提高精度并降低eGFR斜率变异性,可能优化ADPKD试验效率与设计。
研究设计与样本
- DIPAK观察性队列中260例ADPKD患者,比较2021 CKD-EPI公式基于常规临床肌酐、批测肌酐、批测胱抑素C及两者联合的eGFR与mGFR。
主要发现
- 横断面性能:批测eGFRcr与常规eGFRcr大致相似;eGFRcys和eGFRcr-cys偏倚大于eGFRcr;eGFRcr-cys精度最高。
- 纵向:批测eGFRcr-cys斜率与mGFR下降的CCC为0.68(95%CI 0.59-0.76),eGFRcr为0.58(95%CI 0.47-0.67),P=0.02。
- eGFRcr-cys斜率标准差低于eGFRcr和eGFRcys,使临床试验样本量减少37%至38%。
关键数值与推荐
- eGFRcr-cys斜率与mGFR下降的CCC为0.68(95%CI 0.59-0.76),eGFRcr为0.58(95%CI 0.47-0.67),P=0.02。
- eGFRcr-cys斜率变异性降低使临床试验样本量减少37%至38%。
临床怎么用
- 在ADPKD临床试验中可考虑采用eGFRcr-cys作为终点指标以提高精度并减少样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In autosomal dominant polycystic kidney disease (ADPKD) trials, creatinine-based estimated glomerular filtration rate (GFR, eGFRcr) is a key end point; however, variability in creatinine measurements may affect reliability. We compared routine eGFRcr to eGFR derived from batch-measured creatinine, cystatin C (eGFRcys), or both (eGFRcr-cys) using biobanked samples, against iothalamate-measured GFR (mGFR). METHODS: In the 260 patients with ADPKD from the DIPAK observational cohort, we compared 2021 Chronic Kidney Disease (CKD)-Epidemiology Collaboration (CKD-EPI)-based eGFR based on the following: (i) routine clinical creatinine, (ii) batch-measured creatinine, and (iii) batch-measured cystatin C to mGFR. Creatinine and cystatin batch measurements were performed on the same day to minimize variability. Cross-sectional performance was evaluated by bias (eGFR - mGFR), precision, accuracy (P30/P10), and CKD stage agreement. Longitudinal agreement between mGFR and eGFR slopes (ml/min per 1.73 m2/yr) was assessed using concordance correlation coefficients (CCC). Sample size requirements for hypothetical trials were calculated based on slope variability. RESULTS: Cross-sectional performance of batch-measured eGFRcr was largely similar to routine eGFRcr. eGFRcys and eGFRcr-cys showed greater bias than eGFRcr; eGFRcr-cys showed the highest precision. Longitudinally, batch-measured eGFRcr-cys slopes correlated more strongly with mGFR decline than eGFRcr (CCC: 0.68; 95% confidence interval [CI]: 0.59-0.76] vs. 0.58 [95% CI: 0.47-0.67]; P = 0.02). eGFRcr-cys slopes exhibited lower SDs than eGFRcr and eGFRcys. This reduction in slope variability translated to sample size reductions of 37% to 38% for clinical trials. CONCLUSION: The use of eGFRcr-cys enhances precision and reduces eGFR slope variability. Using combined creatinine-cystatin C estimates may optimize trial efficiency and design in ADPKD.
引用
- Bais T, Mohamed AAA, Noruzi A, et al. Combining Cystatin C and Creatinine Increases eGFR Slope Accuracy in ADPKD. Kidney Int Rep. 2026. PMID: 42733501. doi:10.1016/j.ekir.2026.107008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。